초록 ▼

An adjustable magnetic snap fastener for releasably connecting two pieces of material at any one of a number of possible positions. There are a number of stems attached to one plate and a number of magnets attached to another plate. Any one of the stems fits into a hole in any one of the magnets to

An adjustable magnetic snap fastener for releasably connecting two pieces of material at any one of a number of possible positions. There are a number of stems attached to one plate and a number of magnets attached to another plate. Any one of the stems fits into a hole in any one of the magnets to connect the two sections of the fastener and hence the two pieces of material. Alternatively, there are a number of magnets attached to one plate and a number of magnets attached to another plate, oriented so that every one of the magnets on the first plate is attracted to every one of the magnets on the second plate.

대표청구항 ▼

An adjustable magnetic snap fastener for releasably connecting two pieces of material at any one of a number of possible positions. There are a number of stems attached to one plate and a number of magnets attached to another plate. Any one of the stems fits into a hole in any one of the magnets to

An adjustable magnetic snap fastener for releasably connecting two pieces of material at any one of a number of possible positions. There are a number of stems attached to one plate and a number of magnets attached to another plate. Any one of the stems fits into a hole in any one of the magnets to connect the two sections of the fastener and hence the two pieces of material. Alternatively, there are a number of magnets attached to one plate and a number of magnets attached to another plate, oriented so that every one of the magnets on the first plate is attracted to every one of the magnets on the second plate. trate in relation to said printed circuit board to prevent any movement between said substrate in relation to said printed circuit board in the presence of vibrations on said column grid array package. 10. The column grid array package of claim 9, wherein said corner post is made of aluminum. 11. The column grid array package of claim 10, wherein said corner post is attached to said printed circuit board via an epoxy. 12. The column grid array package of claim 11, wherein said epoxy forms a fillet on at least one side between said corner post and said printed circuit board. 13. The column grid array package of claim 12, wherein said epoxy forms a fillet on a corner between a top surface of said substrate and a vertical wall of said corner post. lity of micro-actuators disposed regularly in the reference surface of said bottom slab, each micro-actuator having a moving rod that moves in a direction orthogonal to the reference surface, said rods when in the non-activated position being completely withdrawn relative to said reference surface. 4. The device according to claim 1, wherein said lifting means is mounted on said bottom slab. 5. A device for transferring and supporting a double-sided panel having a bottom face and a top face, in particular a printed circuit panel, said device comprising: a bottom slab having a top reference surface that is planar and horizontal for receiving the bottom face of said panel; a top slab having a bottom reference surface that is planar and horizontal for receiving the top face of said panel; displacement means for moving said slabs separately in two respective horizontal planes; each of said slabs being provided with non-mechanical holder means that are controllable for pressing one face of said panel against the reference surface of said slab, when the holder means are activated; and controllable lifting means mounted on said bottom slab for controlling said panel, said lifting means not projecting from the reference surface of said bottom slab when it is in a non-activated state, and being suitable for pressing said panel against the reference surface of said top slab when it is activated. 6. The device according to claim 5, wherein said holder means comprises suction micro-nozzles opening out in the reference surfaces of said slabs and regularly distributed over said surfaces. 7. The device according to claim 5, wherein said lifting means comprises a plurality of micro-actuators disposed regularly in the reference surface of said bottom slab, each micro-actuator having a moving rod that moves in a direction orthogonal to the reference surface, said rods when in the non-activated position being completely withdrawn relative to said reference surface. 8. The device according to claim 5, wherein said top slab and said bottom are moved in two distinct, fixed horizontal planes. ridecyl) chroman-6-yloxy) acetic acid, 2,8-dimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy) acetic acid, 2-(N,N-(carboxymethyl)-2(2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy) acetic acid, 2,5,7,8-tetramethyl-(2RS-(4RS,8RS,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,5,7,8-tetramethyl-2R-(2RS,6RS,10-trimethylundecyl)chroman-6-yloxy) acetic acid, 3-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl)chroman-6-yloxy)propyl-1-ammonium chloride, 2,5,7,8-tetramethyl-(2R-(4r,8R,12-trimethyltridecyl)chroman-3-ene-6-yloxy) acetic acid, 2-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl) chroman-6-yloxy)triethylammonium sulfate, 6-(2,5,7,8-tetramethyl-(2R(4R,8,12-trimethyltridecyl)chroman)acetic acid, 2,5,7,8,-tetramethyl-(2R-(heptadecyl)chroman)yloxy) acetic acid, and 2,5,7,8,-tetramethyl-2R(4,8,-dimethyl-1,3,7 E:Z nonotrien)chroman-6-yloxy) acetic acid. 3. The method of claim 1, wherein said compound exhibits an anti-proliferative effect comprising apoptosis, DNA synthesis arrest, cell cycle arrest, or cellular differentiation. 4. The method of claim 1, wherein said animal is a human. 5. The method of claim 1, wherein said composition is administered in a dose of from about 1 mg/kg to about 60 mg/kg. 6. The method of claim 1, wherein administration of said composition is selected from the group consisting of oral, topical, intraocular, intranasal, parenteral, intravenous, intramuscular, or subcutaneous. 7. The method of claim 1, wherein said cell proliferative disease is selected from the group consisting of neoplastic diseases and non-neoplastic disorders. 8. The method of claim 7, wherein said neoplastic disease is selected from the group consisting of ovarian cancer, cervical cancer, endometrial cancer, bladder cancer, lung cancer, breast cancer, testicular cancer, prostate cancer, gliomas, fibrosarcomas, retinoblastomas, melanomas, soft tissue sarcomas, ostersarcomas, leukemias, colon cancer, carcinoma of the kidney, pancreatic cancer, basal cell carcinoma, and squamous cell carcinoma. 9. The method of claim 7, wherein said non-neoplastic disease is selected from the group consisting of psoriasis, benign proliferative skin diseases, ichthyosis, papilloma, restinosis, scleroderma, hemangioma, viral diseases, and autoimmune diseases. 10. The method of claim 9, wherein said autoimmune diseases are selected from the group consisting of autoimmune thyroiditis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, dermatitis herpetiformis, celiac disease, and rheumatoid arthritis. 11. The method of claim 7, wherein said non-neoplastic disorders are selected from the group consisting of viral disorders and autoimmune disorders. 12. The method of claim 11, wherein said viral disorder is Human Immunodeficiency Virus. 13. The method of claim 11, wherein said autoimmune disorders are selected from the group consisting of the inflammatory process involved in cardiovascular plaque formation, ultraviolet radiation induced skin damage and disorders involving an immune component. 14. A method of inducing apoptosis of a cell, comprising the step of contacting said cell with a pharmacologically effective dose of a compound having a structural formula: wherein X is oxygen; R1is --C1-10alkylene-COOH --C1-4alkylene-CONH2, --C1-4alkylene-COO--C1-4alkyl, --C1-4alkylene-CON(C1-4alkylene-COOH)2,C1-4alkylene-OH, C1-4alkylene-NH3-halo, or C1-4alkylene-OSO2NH(C1-4alkyl)3; R2,R3are H or C1-4alkyl; R4is C1-4alkyl; and R5is methyl, C7-17alkyl, COOH, C7-17olefinic group containing 3 to 5 ethylenic bonds, --C=C--COO--C1-4alkyl or C1-4alkylene-COO--C1-4alkyl with the proviso that R1cannot be --C2-4alkylene-COOH when R2,R3,and R4are methyl, and R5is a C16alkyl; or a pharmaceutical composition thereof. 15. The method of claim 14, wherein said compound is selected from the group consisting of 2,5,7,8-tetramethyl-(2R(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,5,8-trimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,7,8-trimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,8-dimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy) acetic acid, 2-(N,N-(carboxymethyl)-2(2,5,7,8-tetramethyl-(2R-(4R,8R, 12-trimethyltridecyl) chroman-6-yloxy) acetic acid, 2,5,7,8-tetramethyl-(2RS-(4RS,8RS, 12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,5,7,8-tetramethyl-2R-(2RS,6RS,10-trimethylundecyl)chroman-6-yloxy)acetic acid, 3-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl)chroman-6-yloxy)propyl-1-ammonium chloride, 2,5,7,8-tetramethyl-(2R-(4r,8R,12-trimethyltridecyl)chroman-3-ene-6-yloxy) acetic acid, 2-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl) chroman-6-yloxy)triethylammonium sulfate, 6-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl)chroman)acetic acid,2,5,7,8,-tetramethyl-(2R-(heptadecyl)chroman-6-yloxy) acetic acid, and 2,5,7,8,-tetramethyl-2R-(4,8,-dimethyl-1,3,7 E:Z nonotrien)chroman-6-yloxy) acetic acid. 16. The method of claim 14, wherein said method is useful in the treatment of a cell proliferative disease. according to claim 5 wherein the aqueous methanol has a water content of 5 to 20%. 8. A process according to claim 5 wherein the aqueous methanol has a water content of 7 to 10%. 9. A process for the preparation of the D-(-)-tartrate salt of a compound of formula (I): comprising the steps of (i) dissolving a racemic mixture comprising compounds of formulae (I) and (II) in an aqueous methanol solution having a water content of 5 to 20% in the presence of D-(-)-tartaric acid; and (ii) allowing the D-(-)-.tartrate salt of the compound of formula (I) to separate out of solution. 10. A process according to claim 9 wherein the aqueous methanol has a water content of7to 10%. 11. The D-(-)-tartrate salt of a compound of formula (I): wherein the ratio of the (1S,2S)-enantiomer to its (1R,2R)-antipode is greater than 97%. 12. A salt according to claim 11 wherein the ratio of the (1S,2S)-enantiomer to its (1R,2R)-antipode is greater than 98%.